India’s batsmen need to better seize their chances and aim for longer partnerships if they are to bounce back from their test defeat on Thursday and still win the series in South Africa, said coach Rahul Dravid.
India lost by seven wickets in the second test at the Wanderers on Thursday, which sets up an exciting finale in Cape Town next week with the series level at 1-1.
If India are to win, and in the process take a first-ever series victory in South Africa, they will need to do some sharpening at the top of the batting order, Dravid told a post-match virtual news conference on Thursday.
“The wickets in the first two tests have been a little challenging, I will give that to the batsmen. But we pride ourselves on wanting to do better and the batting unit certainly can look to maybe seize a few key moments and when we get those partnerships, maybe make them a little bit longer," he said.
“In the first innings the ball sort of tended to kick up a little bit, but we could have probably got maybe 60-70 more runs.”
India were bowled out for 202 in their first innings, to which the hosts replied with 229. India then scored 266 in their second innings on a deteriorating pitch to set South Africa an imposing target of 240, which they reached with seven wickets to spare after a doggedly determined batting performance.
“Certainly we'd like to bat a little bit better. We need to keep improving and getting better. Maybe some of the guys who got starts could have converted those into hundreds,” added Dravid.
“I think that was the difference in the first test where KL Rahul went on to get a hundred for us and we ended up on the winning side.
“In the second test, they had someone (Dean Elgar) who ended up on 96 and they ended up on the winning side.
“It really shows you the importance, on these kinds of wickets, of one of your batsman going on and making a big score,” the coach said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.